Abivax S.A. (ABVX) company profile

The entity (operating under the ticker identifier ABVX) operates in biotechnology and therapeutic asset development, conducting research, intellectual property licensing, and contract clinical programs. Its development pipeline centers around project assets such as ABX464 and ABX196, managed in part via licensing contracts and collaborations with research and academic institutions. The filing mentions no retail customer base or direct commercial consumers, indicating an operational emphasis on clinical development, research licensing, and project advancement.

The organization maintains technical facilities and leased premises in Paris, France, where it deploys office equipment, computer software, and specialized operating machinery. In addition to its French infrastructure, the company documents property, contractual relationships, and operations extending across jurisdictions in the United States. No commercial retail stores or store networks are reported in the filing text.

Summary of the business section of Abivax's latest annual report, written by StockData.

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 69 full-time employees, consisting of 49 within the research and”